COMP <GO>
INDV vs LQDA // OPERATING MARGIN
Indivior Pharmaceuticals Inc. (NASDAQ) VS. Liquidia Corporation (NASDAQ) • 15-METRIC TALLY: INDV 6
— LQDA 4
▲ OPERATING MARGIN LEADER: INDV
LAST: $35.37 (+0.34%) • MKT CAP: $4.17B
operating-margins
21.10%
LAST: $45.06 (+0.16%) • MKT CAP: $4.03B
operating-margins
-32.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INDV VS. LQDA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INDV | LQDA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 80.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 62.20% | -12.60% | +74.80 | INDV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.4x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.24% | -0.99% | -1.25 | LQDA | /fcf-yield <GO> |
| Operating Margin ACTIVE | 21.10% | -32.50% | +53.60 | INDV | /operating-margins <GO> |
| Net Profit Margin | 16.90% | -43.50% | +60.40 | INDV | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 180.00% | -175.70 | LQDA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.13 | 6.33 | -3.20 | LQDA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.3 | 52.5 | -0.20 | LQDA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 0.90 | +0.25 | INDV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.4x | 21.0x | -2.60 | INDV | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.17B | $4.03B | $141.6M | INDV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INDV REV | LQDA REV | INDV GROSS % | LQDA GROSS % | INDV FCF | LQDA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.24B | $158.3M | 80.2% | — | -$93.0M | -$40.0M |
| FY 2024 | $1.19B | $14.0M | 80.6% | 58.0% | $7.0M | -$98.4M |
| FY 2023 | $1.09B | $17.5M | — | — | -$349.2M | -$42.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INDV // BETA 1.15
LQDA // BETA 0.90